Managing Moderate Penetrance
|
|
- Preston Hoover
- 6 years ago
- Views:
Transcription
1 Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences City of Hope National Medical Center
2 Disclosures I do not have anything to disclose.
3 Objectives Describe the differences between a high, moderate, and low penetrance cancer susceptibility genes. Counsel a patient about moderate and low penetrance cancer susceptibility genes found on routine clinical i l testing Identify that moderate and low penetrance cancer susceptibility genes may not track with the family history of cancer. Recognize that cancer susceptibility genes on clinical panels are not always actionable.
4 Outline Background Moderate penetrance genes influence on breast, ovarian, and colorectal cancer. Incorporation into management and risk models Conclusions
5 Why are panels expanding? NGS, Patents, Pathways, candidate genes and emerging evidence (may add ~5 10%)
6 Results of MGP testing NBN 10% BRIP1 7% MRE11A 3% BARD1 RAD51D RAD50 2% 2% 2% CHEK2 29% ATM 14% MUTYH mono 14% PALB2 17% Select results from 348 commercial multigene panel tests ordered by Clinical Cancer Genetics Community of Practice clinicians between January 1, 2014, through October 1, Adapted from Slavin T.P. et al., Front. Oncol :208.
7 Aren t more genes better? In theory Value In reality Genes
8 Distinguishing a moderate penetrance gene from a high or low penetrance gene Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR and Weitzel JN (2015) Clinical application of multigene panels: challenges of next-generation counseling and cancer risk management. Front. Oncol :208.
9 Cause of a given cancer High Penetrance gene Other factors
10 Cause of a given cancer Moderate Penetrance gene Other factors
11 Moderate penetrance genes influence on breast, ovarian, and colorectal cancer
12 Breast cancer Gene Average relative risk Breast cancer ATM 2.8 (90% CI ) CHEK2 (truncating) CHEK2 (missense) 3.0 (90% CI ) 1.58 (95% CI ) for I157T NBN 2.7 (90% CI ) for c.657del5 PALB2 5.3 (90% CI ) Adapted from Tung et al Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Vol 13: Also see: Easton, D. F. et al. N. Engl. J. Med. 372, (2015). Han, F. F., Guo, C. L. & Liu, L. H. DNA Cell Biol. 32, (2013).
13 ATM Absolute Risk by 80 ~27% 2 High penetrance Australian variants (c.t7271g, IVS10 6T G; 2002 JNCI) High population prevalence No contraindication to radiation for therapy Bernstein JL and Women s environmental, cancer, and radiation epi study. Radiation Exposure, the ATM Gene, and Contralateral Breast Cancer in the Women's Environmental Cancer and Radiation Epidemiology Study. JNCI J Natl Cancer Inst (2010) 102 (7): Easton, D. F. et al. N. Engl. J. Med. 372, (2015). Chenevix-Trench et al, Dominant Negative ATM Mutations in Breast Cancer Families. JNCI J Natl Cancer Inst (2002) 94 (3): Tung et al Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Vol 13:
14 CHEK2 CHEK2 (truncating) CHEK2 (missense) Absolute risk ~29% Absolute risk ~18% for I157T Easton, D. F. et al. N. Engl. J. Med. 372, (2015). Han, F. F., Guo, C. L. & Liu, L. H. The effect of CHEK2 variant I157T on cancer susceptibility: evidence from a meta-analysis. DNA Cell Biol. 32, (2013).
15 NBN RR: 2.7 (90% CI ) for c.657del5 (ONLY!) Absolute risk ~23% Zhang G, Zeng Y, Liu Z, Wei W. Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk. Tumour Biol 2013; 34:
16 Antoniou AC et al. N Engl J Med 2014;371: PALB2
17 Risk of Breast Cancer for Female PALB2 Mutation Carriers, According to Family History of Breast Cancer. Antoniou AC et al. N Engl J Med 2014;371:
18 Contralateral breast
19 No strong breast cancer association at BARD1 BRIP1 RAD50 RAD51C RAD51D XRCC2 SLX4 this time (2016) Tung et al Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Vol 13:
20 Ovarian Cancer Ovarian cancer BRIP1 RAD51C/RAD51D 11.2 (95% CI ) in case control 3.41 (95% CI ) in segregation analysis 5.2 (95% C.I ) for RAD51C 12 (95% C.I ) for RAD51D Ramus, S. J. et al. Germline mutations in the BRIP1, BARD1, PALB2, and NBN genes in women with ovarian cancer. J. Natl Cancer Inst. 107, djv214 (2015). Song, H. et al. Contribution of germline mutations in the RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J. Clin. Oncol. 33, (2015). Tung et al Counselling framework for moderate penetrance cancer susceptibility mutations. Nature reviews. Vol 13:
21 Tung et al Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Vol 13:
22 PALB2? Among 154 families, relative risk of ovarian cancer among PALB2 mutation carriers was 231(95% 2.31 CI, to 6.97;P = 0.18) 018) Significant in a large case controlled analysis with OR of 10.9 (95% CI ) 4626 Antoniou A.C., et al. Breast Cancer Risk in Families with Mutations in PALB2. N Engl J Med 2014;371: Norquist BM, Harrell MI, Brady MF, et al. Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol. 2016;2(4):
23 No strong ovarian cancer association ATM BARD1 CHEK2 MRE11A NBN RAD50 RAD51B XRCC2 SLX4 at this time (2016) Tung et al Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Vol 13:
24 Colorectal Cancer Colorectal cancer APC I1307K 2.17 (95% C.I ) 1.88 (95% C.I ) for 1100delC CHEK2 156(95% 1.56 C.I. CI ) for I157T MUTYH (monoallelic) 1.17 (95% C.I ) Level associated an affected first-degree relative with CRC (RR 2.25, 95% CI ); APC I1307K and CHEK2 1100delC overlap this range. Liang, J. et al. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta analysis. Am. J. Epidemiol. 177, (2013). Ma, X., Zhang, B. & Zheng, W. Genetic et variants a tsassociated ated with colorectal o cancer ce risk: comprehensive e eresearch synopsis, s, meta analysis, and epidemiological evidence. Gut 63, (2014). Johns, L. E. & Houlston, R. S. A systematic review and meta analysis of familial colorectal cancer risk. Am. J. Gastroenterol. 96, (2001). Tung et al Counselling framework for moderate penetrance cancer susceptibility mutations. Nature reviews. Vol 13:
25
26 Mutation classifications do not indicate penetrance Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of MedicalGenetics and Genomics and the Association for Molecular Pathology. Genet Med May;17(5): Freely available online. IARC Unclassified Genetic Variants Working Group, HUMAN MUTATION 29(11), , 2008 (1) Pathogenic (2) Likely pathogenic (3) Uncertain significance (4) Likely benign (5) Benign
27 Moderate risk CRC gene management
28 Other rare (unclear risk, presumed high h from reported dfamilies) Polymerase proofreading associatedassociated polyposis POLD1 and POLE <50 polyps Early onset CRC and/or adenomas GREM1 Mixed polyposis syndrome due to a 40kb duplication upstream of GREM1 (AJ ancestry) Management: Colonoscopy at 25, q 2 3yrs if negative, 1 2 yrs if polyps (NCCN). Palles C et al. Nat. Genet. 2013Feb;45(2): NCCN Genetic/Familial HR Assiessment:CRC 2016, Version 1 Valle L et al. Hum. Mol. Genet Jul;23(13): Jaeger E, et al. Nat Genet 2012; 44:
29 So BARD1 FANCC MRE11A RAD50 XRCC2 SLX4 RAD51B other NBN
30 Even healthy populations have mutations
31 Managing the Moderate
32 BOADICEA Testing negative for a known familial moderate risk gene mutation does not completely reduce risk to the general population. Lee A.J., et al., Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. Genet Med Apr 14
33 Guidelines change! (2015) NCCN Guidelines Version 1 (2015), Genetic/Familial High-Risk Assessment: Breast and Ovarian
34 Guidelines change! (2016) 2017: PALB2, ages? Recommend carriers check back or set up follow ups NCCN Guidelines Version 1 (2016), Genetic/Familial High-Risk Assessment: Breast and Ovarian
35 APC I1307K? Tung et al Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nature reviews. Vol 13: APC I1307K added.
36 Prenatal/ preimplantation genetics ATM Ataxia telangiectasia telangiectasia BLM Bloom syndrome NBN Nijmegen breakage syndrome Fanconi Anemia pathway genes
37 CHEK2, c.1100delc
38 ATM, c.3802delg
39 Next steps of moderate penetrance: PRS Mavaddatt N. et al, Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst Apr 8;107(5)
40 Summary Moderate penetrance genes should ldbe treated differently than high penetrance genes They may not track with the family history of cancer More research is being done to better define the absolute risk for and spectrum of associated cancers Specific geno pheno correlations (i.e., NBN) Screening recommendations may differ
41
42 Questions?
43
44
Germline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationGermline Multigene Panel Testing in Oncology: Genetic Counseling Perspective
Germline Multigene Panel Testing in Oncology: Genetic Counseling Perspective Sarah L. Campian, MS CGC Certified Genetic Counselor Nancy & James Grosfeld Cancer Genetics Center Objectives Identify patients/families
More informationWhy Test for Hereditary Cancer in Preventive Care?
Why Test for Hereditary Cancer in Preventive Care? Millions of people are sidelined by cancer. Wouldn't it be worth it for your patients to know their risk? background HEREDITARY (5-10%) More than 1 in
More informationModelling cancer risk predictions:clinical practice perspective.
Modelling cancer risk predictions:clinical practice perspective. Judith Balmaña, MD, PhD Familial Cancer Program Medical Oncology Department Hospital Vall d Hebron, VHIO Barcelona, Spain It is very difficult
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME GENE DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationWHAT IS A GENE? CHROMOSOME DNA PROTEIN. A gene is made up of DNA. It carries instructions to make proteins.
WHAT IS A GENE? CHROMOSOME E GEN DNA A gene is made up of DNA. It carries instructions to make proteins. The proteins have specific jobs that help your body work normally. PROTEIN 1 WHAT HAPPENS WHEN THERE
More informationGYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
More informationBRCAplus. genetic testing for hereditary breast cancer
BRCAplus genetic testing for hereditary breast cancer Developed in collaboration with Fox Chase Cancer Center and the Arcadia University Genetic Counseling Program. Causes of Hereditary Breast Cancer familial
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationRole of genetic testing in familial breast cancer outside of BRCA1 and BRCA2
Role of genetic testing in familial breast cancer outside of BRCA1 and BRCA2 Introduction Most commonly diagnosed cancer in South African women and the second most commonly diagnosed cancer in Black women
More informationGYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
More informationBreast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou
Breast and ovarian cancer risk assessment using multigene panel tests Prof Antonis Antoniou Department of Public Health and Primary Care University of Cambridge, U.K. Cancer risk prediction in the era
More informationCentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION
CentoCancer STRIVE FOR THE MOST COMPLETE INFORMATION CentoCancer our most comprehensive oncogenetics panel for hereditary mutations Hereditary pathogenic variants confer an increased risk of developing
More informationAssessment and Management of Genetic Predisposition to Breast Cancer. Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18
Assessment and Management of Genetic Predisposition to Breast Cancer Dr Munaza Ahmed Consultant Clinical Geneticist 2/7/18 Overview The role of the Cancer Genetics team NICE guidelines for Familial Breast
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationGenetic testing for hereditary cancer
Genetic testing for hereditary cancer THE GENETICS OF HEREDITARY CANCER About half of all men and one-third of all women in the US will develop cancer during their lifetimes. Approximately 5% to 10% of
More informationA Patient s Guide to Hereditary Cancer. Is Hereditary Cancer Testing Right for You?
A Patient s Guide to Hereditary Cancer Is Hereditary Cancer Testing Right for You? What is Hereditary Cancer? Most cancers occur in people who do not have a strong family history of that cancer. This is
More informationThe Value of Panel Testing in Inherited Breast Cancer Risk Assessment. Rodney J. Scott Division of Molecular Medicine
The Value of Panel Testing in Inherited Breast Cancer Risk Assessment Rodney J. Scott Division of Molecular Medicine Mutation Detection Next Generation DNA sequencing has revolutionised mutation detection
More informationGermline Genetic Testing for Breast Cancer Risk
Kathmandu, Bir Hospital visit, August 2018 Germline Genetic Testing for Breast Cancer Risk Evidence-based Genetic Screening Rodney J. Scott Demography in New South Wales (total population ~ 7,000,000)
More informationLearn your genetic risk for the most common hereditary cancers.
Learn your genetic risk for the most common hereditary cancers. color.com Color analyzes 30 genes including BRCA1 and BRCA2 to help women and men understand their risk for the most common hereditary cancers,
More informationUse of panel tests in place of single gene tests in the cancer genetics clinic
Clin Genet 2015: 88: 278 282 Printed in Singapore. All rights reserved CLINICAL GENETICS doi: 10.1111/cge.12488 Short Report se of panel tests in place of single gene tests in the cancer genetics clinic
More informationResult Navigator. Positive Test Result: RAD51C. After a positive test result, there can be many questions about what to do next. Navigate Your Results
Result Navigator Positive Test Result: RAD51C Positive test results identify a change, or misspelling, of DNA that is known or predicted to cause an increased risk for cancer. DNA is the blueprint of life
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationHereditary Breast and Ovarian Cancers: Risk Management Recommendations. Objectives
Hereditary Breast and Ovarian Cancers: Risk Management Recommendations Tuya Pal, MD Moffitt Cancer Center Objectives 1 Identify genes associated with Hereditary Breast/Ovarian Cancer, including new and
More informationCarol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center
Carol Christianson, MS, CGC Genetic Counselor West Michigan Cancer Center Following this presentation you will be able to: Identify cancer survivors in your practice who might benefit from genetic counseling
More informationGenetic testing and pancreatic disease
Genetic testing and pancreatic disease February 2 d, 2018 Yale Pancreas Symposium 2018: Multidisciplinary Management of Pancreatic Cancer Xavier Llor, M.D., PhD. Associate Professor of Medicine Co-Director,
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationThe Role of genetic Testing for Inherited Prostate Cancer Risk
FOIU July 2018 The Role of genetic Testing for Inherited Prostate Cancer Risk Leonard G. Gomella, MD Chairman, Department of Urology Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationHereditary Cancer Update Strengthening Linkages Workshop April 22, 2017
Hereditary Cancer Update Strengthening Linkages Workshop April 22, 2017 Renée Perrier, MD MSc FRCPC Clinical Assistant Professor University of Calgary, Department of Medical Genetics Medical Director,
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2017 Origination: 7/2013 Next Review: 7/2018 Policy Blue Cross and Blue Shield of Kansas City
More informationGenetics & Precision Medicine Cancer Care
Genetics & Precision Medicine Cancer Care Johnathan M. Lancaster, MD PhD Chief Medical Officer Myriad Genetics Copyright 2015 Myriad Genetics, Inc., all rights reserved. www.myriad.com. Precision Medicine
More informationA guide to genetic testing for hereditary cancers
Cancer Testing Solutions A guide to genetic testing for hereditary cancers The benefit of knowing TM Hereditary cancer genetic testing can play a critical role in managing health Cancer touches millions
More informationGenetic Testing for Familial Gastrointestinal Cancer Syndromes. C. Richard Boland, MD La Jolla, CA January 21, 2017
Genetic Testing for Familial Gastrointestinal Cancer Syndromes C. Richard Boland, MD La Jolla, CA January 21, 2017 Disclosure Information C. Richard Boland, MD I have no financial relationships to disclose.
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationMultiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer
www.impactjournals.com/oncotarget/ Oncotarget, Supplementary Materials 2016 Multiple gene sequencing for risk assessment in patients with early-onset or familial breast cancer Supplementary Materials Supplementary
More informationP NK. Breast Cancer Genetic Risk Test. Test Report
Test Report CONTENTS SECTION 1 1-1. Patient Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Genes Tested SECTION 2 2-1. About the Test 2-2. References 1-1. Patient Information
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationpatient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext-Expanded genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime
More informationThe benefit of. knowing. Genetic testing for hereditary cancer. A patient support guide
The benefit of knowing Genetic testing for hereditary cancer A patient support guide Does cancer run in your family? Cancer is more common in some families. Sometimes cancer is caused by a change in a
More informationAssessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary?
May 16, 2016 Assessing Your Patient s Breast Cancer Risk: Is Genetic Testing Necessary? Presenter: Emily Kuchinsky, MS, CGC 1 Experiences with Genetic Testing Adverse Events in Cancer Genetic Testing:
More informationpatient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention
patient guide CancerNext genetic testing for hereditary cancer Because knowing your risk can mean early detection and prevention Know the Basics Cancer occurs in about 1 in 3 adults in their lifetime types
More informationUnderstanding Your Positive Result. A guide to understanding your risk and taking action
Understanding Your Positive Result A guide to understanding your risk and taking action 2017 Myriad Genetics, Inc. 320 Wakara Way, Salt Lake City, Utah 84108 PH: 1-800-469-7423 FX: 801-584-3615 1 PART
More informationHereditary Cancer Risk Assessment for Gynecological Cancers. FarrNezhatMD.com
Hereditary Cancer Risk Assessment for Gynecological Cancers FarrNezhatMD.com Image credit: PLOS blogs 5-10% hereditary 10-20% 70-80% sporadic Genetic Changes and Cancer Cancer begins with a genetic
More informationUW359 Ovary 3c 3 Serous Recurrent 68 BRCA1 816delGT BRCA1 del exon 1-2. UW417 Ovary 3c 3 Serous Primary 38 BRCA1 1675delA
Supplementary Table 1. Cases with deleterious germline mutations, somatic HR mutations, and somatic PTEN mutations. ID Site Stage Grade Histology Tumor Age Germline mutation(s) a Somatic HR mutation(s)
More informationMSI positive MSI negative
Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth
More informationFamily Assessment. Objectives. Comprehensive Family History Important Inexpensive Underutilized genetic tool
Besides the BRCA genes, what else to consider in hereditary breast and ovarian cancer? Laurie M. Connors DNP, APNG, FNP-BC, AGN-BC Objectives Evaluate personal & family history to assess risk for hereditary
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationMyriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
More informationMedicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático
Medicina de precisión en cáncer de ovario: Determinación de BRCA germinal y somático Dra. Cristina Martin Lorente Hospital de la Santa Creu i Sant Pau. Barcelona Introduction Ovarian cancer is the fifth
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationCorporate Medical Policy
Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationA pathogenic mutation was identified in the BRCA1 gene.
Hereditary Cancer Risk Test ORDERING PHYSICIAN Dr. Jenny Jones Sample Medical Group 123 Main St. Sample, CA SPECIMEN Type: Saliva Barcode: 223 234234 2343 Collected: Apr 13, 2016 Received: Apr 14, 2016
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationA COMPARISON OF CANCER HISTORIES AND MANAGEMENT OF WOMEN CARRIERS OF CHEK2 TRUNCATING AND MISSENSE MUTATIONS
A COMPARISON OF CANCER HISTORIES AND MANAGEMENT OF WOMEN CARRIERS OF CHEK2 TRUNCATING AND MISSENSE MUTATIONS A Thesis Presented to the Faculty of California State University, Stanislaus In Partial Fulfillment
More informationGenetic Testing Today: What Genes Can Tell Us. Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania
Genetic Testing Today: What Genes Can Tell Us Living Beyond Breast Cancer Conference Kara N. Maxwell, MD, PhD University of Pennsylvania Overview of talk PART 1: Overview of Genetics PART 2: BRCA1/2 PART
More informationAre you at risk of Hereditary Cancer? Your Guide to the Answers
Are you at risk of Hereditary Cancer? Your Guide to the Answers What is Hereditary Cancer? The genes we are born with may contribute to our risk of developing certain types of cancer, including breast,
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: July 15, 2018 Related Policies: None Genetic Testing for PTEN Hamartoma Tumor Syndrome Description The PTEN hamartoma tumor syndrome (PHTS) includes several syndromes
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationGynecologic Cancers are many diseases. Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine. Speaker Disclosure:
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Advances in Internal Medicine Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationGynecologic Cancers are many diseases. Speaker Disclosure: Gynecologic Cancer Care in the Age of Precision Medicine. Controversies in Women s Health
Gynecologic Cancer Care in the Age of Precision Medicine Gynecologic Cancers in the Age of Precision Medicine Controversies in Women s Health Lee-may Chen, MD Department of Obstetrics, Gynecology & Reproductive
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Cancer Susceptibility Panels Using Next Generation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_cancer_susceptibility_panels_using_next_generation_sequencing
More informationCancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2
AWARD NUMBER: W81XWH-15-1-0084 TITLE: Cancer Risks Associated With Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2 PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING
More informationDNA Genetic Cancer Risk Test. Test Report
Test Report CONTENTS SECTION 1 1-1. Customer Information 1-2. Test Report Summary 1-3. Test Report Details 1-4. List of Cancers / Tumors Tested SECTION 2 2-1. About the Test 2-2. References 1 CL0040-1_B
More informationObjectives. Genetics in Cancer Treatment and Prevention. Genes
Objectives Genetics in Cancer Treatment and Prevention Cheryl LaFlore, ARNP, MSN, BC Understand how to integrate genetic and genomic information into oncology nursing practice Define the role of an oncology
More informationThe Role of Genetics in Ovarian Cancer Screening. Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno
The Role of Genetics in Ovarian Cancer Screening Dawn DeLozier, Ph.D. Medical Geneticist, SAMC Associate Professor UCSF-Fresno How Much Breast and Ovarian Cancer Is Hereditary? 15%-20% 5%-10% Breast Cancer
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Page 1 of 35 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Cancer Susceptibility
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationInsights. Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version
NCCN Guidelines Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian 9 NCCN Guidelines Insights Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017 Featured Updates
More informationpatient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention
patient guide BreastNext genetic testing for hereditary breast cancer Because knowing your risk can mean early detection and prevention Know the Basics Breast cancer is the most common cancer in women
More informationFeasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015
Feasibility of Clinical Trial Implementation Genetically Eligible Prostate Cancer Patients Oliver Sartor, MD Cathryn E, Garvey, MS December 3, 2015 Study Name Feasibility of Patient Population for proposed
More informationGenetic Cancer Susceptibility Panels Using Next Generation Sequencing
Genetic Cancer Susceptibility Panels Using Next Generation Sequencing Policy Number: 2.04.93 Last Review: 7/2018 Origination: 7/2013 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City
More informationManagement of BRCA Positive Breast Cancer. Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH
Management of BRCA Positive Breast Cancer Archana Ganaraj, MD February 17, 2018 UPDATE ON WOMEN S HEALTH The number of American women who have lost their lives to breast cancer outstrips the total number
More informationPredictive and Diagnostic Testing for Cancer in Women. Aparna Rajadhyaksha MD
Predictive and Diagnostic Testing for Cancer in Women Aparna Rajadhyaksha MD Hereditary Cancer s in Women BRCA1 &2 Other Breast Cancer Genes Li Fraumeni PTEN CHEK2 BRCA1&2 t BRCA1 is part of a complex
More informationHEREDITY & CANCER: Breast cancer as a model
HEREDITY & CANCER: Breast cancer as a model Pierre O. Chappuis, MD Divisions of Oncology and Medical Genetics University Hospitals of Geneva, Switzerland Genetics, Cancer and Heredity Cancers are genetic
More informationPMS2 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table
PMS2 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) PMS2 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationBe Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing.
Be Ready Pack Learn more about how Myriad myrisk is revolutionizing hereditary cancer testing. Hereditary cancer and you Approximately 5% to 10% of all cancers develop because a person inherited a genetic
More informationPersonalised medicine: Past, present and future
Kathmandu, Bir Hospital visit, August 2018 Personalised medicine: Past, present and future Rodney J. Scott University of Newcastle, NSW, Australia & Hunter Area Pathology Service Current Medical Care Started
More informationEvaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes
Evaluation of BRCA1/2 and homologous recombination defects in ovarian cancer and impact on clinical outcomes Melinda S. Yates, PhD Department of Gynecologic Oncology & Reproductive Medicine University
More informationAccepted Manuscript. Utility of Genetic Testing in Persons with Multiple Colorectal Polyps. Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS
Accepted Manuscript Utility of Genetic Testing in Persons with Multiple Colorectal Polyps Natalia Khalaf, MD, MPH, Niloy Jewel Samadder, MD, MS PII: S1542-3565(19)30259-9 DOI: https://doi.org/10.1016/j.cgh.2019.03.007
More informationOvaNext. patient guide. genetic testing for hereditary breast, ovarian, and uterine cancer
patient guide OvaNext genetic testing for hereditary breast, ovarian, and uterine cancer Because knowing your risk can mean early detection and prevention About half of the women diagnosed with uterine
More informationModerate Penetrance Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk
Moderate Penetrance Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk Policy Number: 2.04.126 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross
More informationHereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
More informationMRC-Holland MLPA. Description version 18; 09 September 2015
SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS. Family Health Clinical Genetics. Clinical Genetics department
GENETIC MANAGEMENT OF A FAMILY HISTORY OF FAP or MUTYH ASSOCIATED POLYPOSIS Full Title of Guideline: Author (include email and role): Division & Speciality: GUIDELINES FOR THE GENETIC MANAGEMENT OF A FAMILY
More informationMSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table
MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14 REVISED DATE: 10/15/15, 10/20/16, 01/18/18
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY REVISED DATE: 10/15/15, 10/20/16, 01/18/18 PAGE: 1 OF: 10 If a product excludes coverage for a service, it is not covered, and medical policy
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationGenetic Risk Assessment for Cancer
Genetic Risk Assessment for Cancer Jennifer Siettmann, MS CGC Certified Genetic Counselor/Cancer Risk Counselor Banner Good Samaritan Cancer Screening & Prevention Program Objectives Describe the role
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More informationThe lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):
DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence
More informationLearning Objectives. Page 1
Learning Objectives 1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation. 2. Explore recent advances in
More informationPanel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research
Panel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research Malaysia E mail: soohwang.teo@cancerresearch.my How much of
More informationMEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY TO HEREDITARY CANCERS EFFECTIVE DATE: 06/19/14, 09/15/15.
MEDICAL POLICY SUBJECT: GENETIC TESTING FOR SUSCEPTIBILITY PAGE: 1 OF: 7 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases,
More informationPopulations Interventions Comparators Outcomes Individuals: With a personal and/or family history suggesting an inherited cancer syndrome
Genetic Cancer Susceptibility Panels Using Next- Generation (20493) Medical Benefit Effective Date: 01/01/18 Next Review Date: 09/18 Preauthorization No Review Dates: 09/13, 09/14, 09/15, 09/16, 09/17
More informationGENETIC TESTING FOR HEREDITARY CANCER
UnitedHealthcare Oxford Clinical Policy GENETIC TESTING FOR HEREDITARY CANCER Policy Number: DIAGNOSTIC 004.27 T2 Effective Date: November 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More information